Abstract
The immune response after hepatitis B (HB) vaccine HEVAC B was studied in 33 children (mean age 10±4 years) with advanced renal failure. Responders and protected patients were defined by antibody titres to HB surface antigen (anti-HBs) of greater than 10 and 50 mIU/ml, respectively. All received the initial recommended three injections at monthly intervals, and 23 received a booster injection (IB) 11±1 months after the third injection (I3). Loss of protection after I3 led to additional injections in 8 patients (25%). Vaccine was well tolerated and no HB infection occurred during the follow-up period (19±10 months). The percentage of responders was 91% 2±1 months after I3, and 100% 1 month, 13±1 months and 26±2 months after IB. The percentages of protected patients at these dates were 91%, 95%, 100% and 100%. Anti-HBs titres 1–3 months after I3 were useful for indicating those patients likely to have a rapid decline in anti-HBs titres, thus requiring serial anti-HBs determinations and additional injections to prevent a loss of protection. We conclude that, at the expense of a reinforced vaccination schedule in 25% of patients, HEVAC B vaccine can safely achieve a sustained protection in more than 90% of uracmic children.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Parfrey PS, Forbes RDC, Hutchinson TA, Baudouin JG, Dauphinee WD, Hollomby DJ Guttman RD (1984) The clinical and pathological course of hepatitis B liver disease in renal transplant recipients. Transplantation 37:461–466
Crosnier J, Jungers P, Courouce AM, Laplanche A, Benhamou E, Degos G, Lacour B, Prunet P, Cerisier Y, Guesry P (1981) Randomised placebo controlled trial of Hepatitis B surface antigen vaccine in French hemodialysis units. I. Medical staff. Lancet I: 455–459
Jilg W, Schmidt M, Deinhardt F, Zachoval R (1984) Hepatitis B vaccination: how long does protection last? Lancet II:458
Köhler H, Arnold W, Renschin G, Dormeyer HH, Meyer zum Büschenfelde KH (1984) Active Hepatitis B vaccination of dialysis patients and medical staff. Kidney Int 125:124–128
Bommer J, Rambausek M, Jilg W, Deinhardt F, Koch HG, Darai G, Bommer G, Rambausek M, Ritz E (1984) Vaccination against hepatitis B in patients with renal insufficiency. Proc Eur Dial Transplant Assoc 21:300–305
Benhamou E, Courouce AM, Laplanche A, Jungers P, Tron JF, Crosnier J (1986) Long term results of Hepatitis B vaccination in patients on dialysis. N Engl J Med 314:1710–1711
Piazza M, Picciotto L, Villari R, Guadagnino V, Orlando R, Macchia V, Memoli AM, Vegnente A, Guida S, Fusco C (1985) Two-dose Hepatitis B immunisation regimen for infants. Lancet II:1120–1121
Maupas P, Chiron JP, Barin F, Coursaget P, Goudeau P, Perrin J, Denis F, Diopmar I (1981) Efficacy of Hepatitis B vaccine in prevention of early HBs Ag carrier state in children. Controlled trial in an endemic area (Senegal). Lancet I:289–292
Callis LM, Clanxet J, Fortuny G, Caballeria J, Carrasco JL, Lardinois R (1985) Hepatitis B virus infection and vaccination in children undergoing hemodialysis. Acta Paediatr Scand 74:213–218
Nivet H, Drucker J, Dubois F, Goudeau A, Coursaget P, Rolland JC, Grenier B, Maupas P (1982) Vaccine against Hepatitis B in children: prevention of Hepatitis B in a pediatric hemodialysis unit. Int J Pediatr Nephrol 3:25–28
Stevens CE, Alter HJ, Taylor PE, Zang EA, Harley EJ, Szmuness W and the Dialysis Vaccine Trial Study Group (1984) Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy. N Engl J Med 311:496–501
Crosnier J, Jungers P, Courrouce AM, Laplanche A, Benhamou, E, Degos F, Lacour B, Prunet P, Cerisier Y, Guesry P (1981) Randomised placebo-controlled trial of Hepatitis B surface antigen vaccine in French hemodialysis units. II: Hemodialysis patients. Lancet II:797–800
Bergamini F, Zanetti AR, Ferroni P, Tanzi E, Minetti L, Perego A, Civati G, Mecca G, Licini M, Sereni F, Ghio L, Piccoli P (1983) Immune response to Hepatitis B vaccine in staff and patients in renal dialysis units. J Infect 7 [Suppl I]:35–40
Laplanche A, Courrouce AM, Jungers P, Benhamou E, Crosnier J (1984) Hepatitis B vaccination: how long does protection last? Lancet II:866
Matsaniotis N, Kattamis C, Laskani S, Dionysopoulou E, Liapaki C (1983) Immunogenicity and efficacy of Hepatitis B vaccine in normal children and in patients with thalassemia. J Infect 7 [Suppl I]: 57–61
Jungers P, Chauveau P, Courouce AM, Mattlinger B, Crosnier J (1985) Hepatitis B vaccine in non dialysed uremic patients: preliminary results. Proc Eur Dial Transplant Assoc 22:1073–1076
Benhamou E, Courouce AM, Jungers P, Laplanche A, Degos F, Brangier J, Crosnier J (1984) Hepatitis B vaccine: randomized trial of immunogenicity in hemodialysis patients. Clin Nephrol 21: 143–147
Bommer J, Ritz E, Andrassy K, Bommer G, Deinhardt F, Jilg W, Darai G (1983) Effect of vaccination schedule and dialysis on hepatitis B response in uraemic patients. Proc Eur Dial Transplant Assoc 20:161–168
Desmytter J, Colaert J, Groote G de, Reynders M, Reerink-Brongers EE, Lelie PN, Dees PJ, Reesink HW (1983) Efficacy of heat-inactivated Hepatitis B vaccine in hemodialysis patients and staff. Doubleblind placebo-controlled trial. Lancet II:1322–1327
Manucci PM, Zanetti AR (1987) Hepatitis B vaccine. N Engl J Med 316:48
Pead PJ, Saeed AA, Hewitt WG, Brownfield RN (1985) Low immune responses to hepatitis B vaccination among healthy subjects. Lancet I:1152
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pillion, G., Chiesa, M., Maisin, A. et al. Immunogenicity of hepatitis B vaccine (HEVAC B) in children with advanced renal failure. Pediatr Nephrol 4, 627–629 (1990). https://doi.org/10.1007/BF00858639
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00858639